No Data
Express News | Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
IGM Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 119.3% Wedbush → $20 Reiterates Outperform → Outperform 04/18/2024 31.58% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
Express News | IGM Biosciences Inc : RBC Cuts Target Price to $20 From $21
IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Pinchie McPincher : theye just announced updated formluation of fostrox
Pinchie McPincher : just announced updated formulation of fostrox , criticsal to support planned study with accelrated approval intent in 2nd lineHCC